eNOS Antibodies

Target Information

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1. Belongs to the NOS family. Platelets, placenta, liver and kidney. 3 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

cNOS; Constitutive NOS; EC-NOS; ECNOS; Endothelial NOS; eNOS; Nitric oxide synthase 3; nitric oxide synthase 3 (endothelial cell); nitric oxide synthase 3 transcript variant eNOS-delta20; nitric oxide synthase 3 transcript variant eNOS-delta20-21; nitric oxide synthase 3 transcript variant eNOS-delta21; Nitric oxide synthase, endothelial; NOS type III; NOS3; NOSIII